Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.

por Miles, D. W., Aderka, D., Engelmann, H., Wallach, D., Balkwill, F. R.
Publicado 1992

Suppressive effect of TNF-α and IL-1 on alveolar fibroblast proliferation in sarcoidosis

por Fireman, E., Aderka, D., Efraim, S. Ben, Greif, J., Wallach, D., Topilsky, M.
Publicado 1992

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

por Golan, T, Kanji, Z S, Epelbaum, R, Devaud, N, Dagan, E, Holter, S, Aderka, D, Paluch-Shimon, S, Kaufman, B, Gershoni-Baruch, R, Hedley, D, Moore, M J, Friedman, E, Gallinger, S
Publicado 2014

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

por Stintzing, S, Wirapati, P, Lenz, H -J, Neureiter, D, Fischer von Weikersthal, L, Decker, T, Kiani, A, Kaiser, F, Al-Batran, S, Heintges, T, Lerchenmüller, C, Kahl, C, Seipelt, G, Kullmann, F, Moehler, M, Scheithauer, W, Held, S, Modest, D P, Jung, A, Kirchner, T, Aderka, D, Tejpar, S, Heinemann, V
Publicado 2019